Pegenzileukin not checked

Sanofi · THOR-707 · SAR444245

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
8 in total · 3 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Pharmaceutical form: Solution for infusion; Route of administration: Intravenous”In the company’s words, NCT04643002 on ClinicalTrials.gov
Tested for
Plasma Cell Myeloma Refractory
Main trialPhase 1/2
“The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.”In the company’s words, NCT04643002 on ClinicalTrials.gov
Other names
THOR-707 · SAR444245

Other drugs for Plasma Cell Myeloma Refractory

All 133 drugs for Plasma Cell Myeloma Refractory

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 13 Sep 2027 Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Phase 2Terminated 18 Jul 2023 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Phase 2Terminated 21 Jul 2023 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
Phase 2Completed 26 Jul 2023 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Phase 2Terminated 14 Sep 2023 A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
Phase 1/2Terminated 22 Aug 2023 A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Phase 1/2Terminated 2 Dec 2025 A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)
Phase 1/2Ended not given Phase 1/2 trial evaluating isatuximab in combination with pegenzileukin in relapsed or refractory multiple myeloma (RRMM) previously exposed to anti-CD38 and anti-BCMA
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Pegenzileukin

Following is part of Solo: you see every change to Pegenzileukin the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in